4-(4-Fluorophenyl)-2-methyl-3-(1-oxy-4-pyridyl)isoxazol-5(2 H )-one (original) (raw)

The study investigates the crystal structure of a new isoxazolone derivative, 4-(4-fluorophenyl)-2-methyl-3-(1-oxy-4-pyridyl)isoxazol-5(2H)-one, which aims to evaluate its potential as a p38 MAPK inhibitor. Structural analysis reveals dihedral angles indicative of interactions that could influence biological activity. This research contributes to the exploration of novel p38 MAPK inhibitors that could improve pharmacokinetic profiles and reduce liver toxicities associated with existing compounds.